The Department of Health has published the full texts of the Framework Agreement on the Supply and Pricing of Medicines 2026–2029 (FASPM), moving the multi-year deal from its March announcement into an operational phase. The publication provides the definitive governance structures for the Irish Pharmaceutical Healthcare Association (IPHA) and Medicines for Ireland, formalising the framework for the next agreement cycle.
As previously reported following the initial March announcement, these agreements establish the fiscal and supply parameters for the Irish market through 2029. The published documents now codify the specific reimbursement procedures and price-realignment mechanisms that will govern both patented and off-patent sectors.
The publication confirms the administrative details for supply commitments intended to mitigate medicine shortages. By providing the operative text, the government has set the procedural baseline for market entry and price reviews – shifting the focus from high-level strategic intent toward practical implementation. These documents will likely standardise the industry–state interface for the remainder of the decade, providing a predictable pathway for access and pricing.
Source: Department of Health
Link: The Framework Agreement on the Supply and Pricing of Medicines (FASPM) 2026-2029
Date: 8 April 2026
